The growth in the historic period can be attributed to established childhood vaccination schedules, historical diphtheria outbreaks, public health immunization mandates, proven safety of dtap vaccines, school entry vaccination requirements.
The growth in the forecast period can be attributed to continued expansion of pediatric healthcare access, stronger disease surveillance, improved vaccine delivery infrastructure, global immunization initiatives, rising parental awareness. Major trends in the forecast period include strengthening pediatric immunization programs, rising coverage of routine childhood vaccines, improved awareness of pertussis prevention, expansion of combination vaccines, government support for early life immunization.
The rising prevalence of infectious diseases is expected to drive the growth of the Daptacel market in the coming years. Infectious diseases are caused by pathogenic microorganisms such as bacteria, viruses, fungi, or parasites and can spread through person-to-person contact, vectors like insects, contaminated surfaces or food, air, bodily fluids, or direct interaction with infected individuals. Factors such as globalization, climate change, antibiotic resistance, poor sanitation, and gaps in vaccination coverage have contributed to the faster spread and emergence of new pathogens. Daptacel, a vaccine for diphtheria, tetanus, and pertussis, helps curb the prevalence of these infectious diseases by stimulating immune protection in individuals. Widespread vaccination significantly reduces the incidence of these diseases within communities. For example, in August 2024, the UK Health Security Agency reported that in 2023, approximately 328 diphtheria cases were confirmed from 278 individuals (170 humans and 108 animals) in England, compared to 253 cases in 2022. Consequently, the rising prevalence of infectious diseases is fueling the growth of the Daptacel market.
The increase in global travel and mobility is also expected to support the growth of the daptacel market. Advances in transportation and the globalization of trade and business have made international travel more accessible and frequent. The growth of tourism and cultural exchange, combined with improved connectivity, has further enhanced global mobility. Daptacel is crucial for international travelers, providing protection against diphtheria, tetanus, and pertussis, and reducing the risk of disease transmission across borders. For instance, in October 2024, Eurostat reported that in 2023, the EU recorded nearly 2.9 billion nights spent in accommodations, with 1.6 billion by international guests, compared to 2.8 billion nights in 2022. Notably, 15.6% of nights spent by international guests were by tourists from regions outside Europe, up from 12.6% in 2022. Therefore, the growth of global travel and mobility is propelling the expansion of the daptacel market.
In November 2024, Amundi SA, a France-based asset management firm, acquired shares of Sanofi SA. Through this acquisition, Amundi aims to strengthen its position in asset management and pursue responsible investment strategies by securing a significant stake in Sanofi SA. Sanofi SA is a France-based pharmaceutical company that develops and delivers medicines and vaccines, including daptacel.
Major companies operating in the daptacel market are Sanofi S.A.
North America was the largest region in the daptacel market in 2025. The regions covered in the daptacel market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the daptacel market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Tariffs have affected the daptacel market by increasing costs of imported vaccine components, syringes, and cold chain logistics. These impacts are more evident in regions dependent on cross border pediatric vaccine supply chains such as asia pacific. Public immunization programs have faced procurement cost pressures. However, tariffs have encouraged localized vaccine packaging and distribution. This supports sustained availability of pediatric vaccines.
The daptacel market research report is one of a series of new reports that provides daptacel market statistics, including daptacel industry global market size, regional shares, competitors with a daptacel market share, detailed daptacel market segments, market trends and opportunities, and any further data you may need to thrive in the daptacel industry. This daptacel market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Daptacel is a DTaP vaccine that protects children under 7 years against diphtheria, tetanus, and pertussis (whooping cough). It is included in the routine immunization schedule for children aged 6 weeks to 6 years to prevent potentially serious bacterial diseases.
The main technology types of daptacel include conjugate, live, recombinant, inactivated, and toxoid vaccines. Conjugate vaccines link a weak antigen to a strong antigen, enhancing the immune response to the weak antigen, and Daptacel conjugate vaccines are commonly used to strengthen immunity in children. Indications cover diphtheria, pertussis, and tetanus for pediatric and adult age groups. Distribution occurs through hospital pharmacies, retail pharmacies, and online pharmacies, serving end users such as hospitals and clinics.
The daptacel market consists of sales of single-dose vials and multi-dose vials. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The growth in the forecast period can be attributed to continued expansion of pediatric healthcare access, stronger disease surveillance, improved vaccine delivery infrastructure, global immunization initiatives, rising parental awareness. Major trends in the forecast period include strengthening pediatric immunization programs, rising coverage of routine childhood vaccines, improved awareness of pertussis prevention, expansion of combination vaccines, government support for early life immunization.
The rising prevalence of infectious diseases is expected to drive the growth of the Daptacel market in the coming years. Infectious diseases are caused by pathogenic microorganisms such as bacteria, viruses, fungi, or parasites and can spread through person-to-person contact, vectors like insects, contaminated surfaces or food, air, bodily fluids, or direct interaction with infected individuals. Factors such as globalization, climate change, antibiotic resistance, poor sanitation, and gaps in vaccination coverage have contributed to the faster spread and emergence of new pathogens. Daptacel, a vaccine for diphtheria, tetanus, and pertussis, helps curb the prevalence of these infectious diseases by stimulating immune protection in individuals. Widespread vaccination significantly reduces the incidence of these diseases within communities. For example, in August 2024, the UK Health Security Agency reported that in 2023, approximately 328 diphtheria cases were confirmed from 278 individuals (170 humans and 108 animals) in England, compared to 253 cases in 2022. Consequently, the rising prevalence of infectious diseases is fueling the growth of the Daptacel market.
The increase in global travel and mobility is also expected to support the growth of the daptacel market. Advances in transportation and the globalization of trade and business have made international travel more accessible and frequent. The growth of tourism and cultural exchange, combined with improved connectivity, has further enhanced global mobility. Daptacel is crucial for international travelers, providing protection against diphtheria, tetanus, and pertussis, and reducing the risk of disease transmission across borders. For instance, in October 2024, Eurostat reported that in 2023, the EU recorded nearly 2.9 billion nights spent in accommodations, with 1.6 billion by international guests, compared to 2.8 billion nights in 2022. Notably, 15.6% of nights spent by international guests were by tourists from regions outside Europe, up from 12.6% in 2022. Therefore, the growth of global travel and mobility is propelling the expansion of the daptacel market.
In November 2024, Amundi SA, a France-based asset management firm, acquired shares of Sanofi SA. Through this acquisition, Amundi aims to strengthen its position in asset management and pursue responsible investment strategies by securing a significant stake in Sanofi SA. Sanofi SA is a France-based pharmaceutical company that develops and delivers medicines and vaccines, including daptacel.
Major companies operating in the daptacel market are Sanofi S.A.
North America was the largest region in the daptacel market in 2025. The regions covered in the daptacel market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the daptacel market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Tariffs have affected the daptacel market by increasing costs of imported vaccine components, syringes, and cold chain logistics. These impacts are more evident in regions dependent on cross border pediatric vaccine supply chains such as asia pacific. Public immunization programs have faced procurement cost pressures. However, tariffs have encouraged localized vaccine packaging and distribution. This supports sustained availability of pediatric vaccines.
The daptacel market research report is one of a series of new reports that provides daptacel market statistics, including daptacel industry global market size, regional shares, competitors with a daptacel market share, detailed daptacel market segments, market trends and opportunities, and any further data you may need to thrive in the daptacel industry. This daptacel market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Daptacel is a DTaP vaccine that protects children under 7 years against diphtheria, tetanus, and pertussis (whooping cough). It is included in the routine immunization schedule for children aged 6 weeks to 6 years to prevent potentially serious bacterial diseases.
The main technology types of daptacel include conjugate, live, recombinant, inactivated, and toxoid vaccines. Conjugate vaccines link a weak antigen to a strong antigen, enhancing the immune response to the weak antigen, and Daptacel conjugate vaccines are commonly used to strengthen immunity in children. Indications cover diphtheria, pertussis, and tetanus for pediatric and adult age groups. Distribution occurs through hospital pharmacies, retail pharmacies, and online pharmacies, serving end users such as hospitals and clinics.
The daptacel market consists of sales of single-dose vials and multi-dose vials. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Daptacel Market Characteristics
3. Daptacel Market Supply Chain Analysis
4. Global Daptacel Market Trends and Strategies
5. Daptacel Market Analysis of End Use Industries
7. Global Daptacel Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Daptacel Total Addressable Market (TAM) Analysis for the Market
9. Daptacel Market Segmentation
10. Daptacel Market Regional and Country Analysis
11. Asia-Pacific Daptacel Market
12. China Daptacel Market
13. India Daptacel Market
14. Japan Daptacel Market
15. Australia Daptacel Market
16. South Korea Daptacel Market
17. Western Europe Daptacel Market
18. UK Daptacel Market
19. Germany Daptacel Market
20. France Daptacel Market
21. Eastern Europe Daptacel Market
22. North America Daptacel Market
23. USA Daptacel Market
24. Canada Daptacel Market
25. South America Daptacel Market
26. Middle East Daptacel Market
27. Africa Daptacel Market
29. Daptacel Market Competitive Landscape and Company Profiles
32. Daptacel Market High Potential Countries, Segments and Strategies
33. Appendix
Executive Summary
Daptacel Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses daptacel market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for daptacel? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The daptacel market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Technology: Inactivated; Toxoid2) By Indication: Diphtheria; Pertussis; Tetanus
3) By Age Group: Pediatric; Adult
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies
5) By End-Use: Hospitals; Clinics
Companies Mentioned: Sanofi S.A
Countries: Australia; India; China; South Korea; Japan; UK; France; Germany; USA; Canada.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Daptacel market report include:- Sanofi S.A
